{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:57:07Z","timestamp":1790819827159,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":312,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04108-4","type":"journal-article","created":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T14:14:27Z","timestamp":1763907267000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stratifin as a biomarker for predicting progression and prognosis in endometrial cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Jing","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-xin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"issue":"1","key":"4108_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41572-021-00324-8","volume":"7","author":"V Makker","year":"2021","unstructured":"Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, Oaknin A. Endometrial cancer. Nat Rev Dis Primers. 2021;7(1):88. https:\/\/doi.org\/10.1038\/s41572-021-00324-8.","journal-title":"Nat Rev Dis Primers"},{"key":"4108_CR2","unstructured":"Key Statistics for Endometrial Cancer. Available online: https:\/\/www.cancer.org\/cancer\/types\/endometrial-cancer\/about\/key-statistics.html (accessed on 26 February 2024)."},{"issue":"9","key":"4108_CR3","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1158\/1055-9965.EPI-18-0264","volume":"27","author":"AS Felix","year":"2018","unstructured":"Felix AS, Brinton LA. Cancer progress and priorities: uterine cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(9):985\u201394. https:\/\/doi.org\/10.1158\/1055-9965.EPI-18-0264.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"4108_CR4","first-page":"468","volume":"93","author":"MM Braun","year":"2016","unstructured":"Braun MM, Overbeek-Wager EA, Grumbo RJ. Diagnosis and management of endometrial cancer. Am Fam Physician. 2016;93(6):468\u201374.","journal-title":"Am Fam Physician"},{"issue":"10333","key":"4108_CR5","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/S0140-6736(22)00323-3","volume":"399","author":"EJ Crosbie","year":"2022","unstructured":"Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. Lancet. 2022;399(10333):1412\u201328. https:\/\/doi.org\/10.1016\/S0140-6736(22)00323-3.","journal-title":"Lancet"},{"key":"4108_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ygyno.2023.02.009","volume":"171","author":"A Gadducci","year":"2023","unstructured":"Gadducci A, Multinu F, De Vitis LA, Cosio S, Carinelli S, Aletti GD. Endometrial stromal tumors of the uterus: Epidemiology, pathological and biological features, treatment options and clinical outcomes. Gynecol Oncol. 2023;171:95\u2013105. https:\/\/doi.org\/10.1016\/j.ygyno.2023.02.009.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"4108_CR7","doi-asserted-by":"publisher","first-page":"2373937","DOI":"10.1080\/01443615.2024.2373937","volume":"44","author":"H Lin","year":"2024","unstructured":"Lin H, Zhong W, Zhong L, Que C, Lin X. The inflammatory markers combined with CA125 May predict postoperative survival in endometrial cancer. J Obstet Gynaecol. 2024;44(1):2373937. https:\/\/doi.org\/10.1080\/01443615.2024.2373937.","journal-title":"J Obstet Gynaecol"},{"issue":"1","key":"4108_CR8","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.1038\/s41467-022-33160-9","volume":"13","author":"N Arakawa","year":"2022","unstructured":"Arakawa N, Ushiki A, Abe M, Matsuyama S, Saito Y, Kashiwada T, Horimasu Y, Gemma A, Tatsumi K, Hattori N, Tsushima K, Miyashita K, Saito K, Nakamura R, Toyoda T, Ogawa K, Sato M, Takamatsu K, Mori K, Nishiya T, Izumi T, Ohno Y, Saito Y, Hanaoka M. Stratifin as a novel diagnostic biomarker in serum for diffuse alveolar damage. Nat Commun. 2022;13(1):5854. https:\/\/doi.org\/10.1038\/s41467-022-33160-9.","journal-title":"Nat Commun"},{"issue":"8","key":"4108_CR9","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1593\/neo.13804","volume":"15","author":"TS Nagaria","year":"2013","unstructured":"Nagaria TS, Williams JL, Leduc C, Squire JA, Greer PA, Sangrar W. Flavopiridol synergizes with Sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR\/HER-2 and mutant RAS\/RAF breast cancer model systems. Neoplasia. 2013;15(8):939\u201351. https:\/\/doi.org\/10.1593\/neo.13804.","journal-title":"Neoplasia"},{"key":"4108_CR10","doi-asserted-by":"publisher","first-page":"9731675","DOI":"10.1155\/2023\/9731675","volume":"2023","author":"SP Ye","year":"2023","unstructured":"Ye SP, Yu HX, Lu WJ, Wang JF, Li TY, Shi J, Cheng XY. Stratifin promotes hepatocellular carcinoma progression by modulating the Wnt\/\u03b2-Catenin pathway. Int J Genomics. 2023;2023:9731675. https:\/\/doi.org\/10.1155\/2023\/9731675.","journal-title":"Int J Genomics"},{"issue":"1","key":"4108_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12967-025-06081-6","volume":"23","author":"B Wang","year":"2025","unstructured":"Wang B, Bao L, Li X, Sun G, Yang W, Xie N, Lei L, Chen W, Zhang H, Chen M, Zhao X, Wan X, Yuan R, Jiang H. Identification and validation of the important role of KIF11 in the development and progression of endometrial cancer. J Transl Med. 2025;23(1):48. https:\/\/doi.org\/10.1186\/s12967-025-06081-6.","journal-title":"J Transl Med"},{"issue":"1","key":"4108_CR12","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s40001-025-02293-0","volume":"30","author":"K He","year":"2025","unstructured":"He K, Zheng J, Zhang T, Lv H, Wang K, Wang Z, Wang L, Wu S, Zhao L. CPA4 overexpression correlates with poor prognosis and tumor progression in endometrial cancer. Eur J Med Res. 2025;30(1):174. https:\/\/doi.org\/10.1186\/s40001-025-02293-0.","journal-title":"Eur J Med Res"},{"issue":"1","key":"4108_CR13","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1186\/s12885-024-12827-0","volume":"24","author":"M Uomoto","year":"2024","unstructured":"Uomoto M, Ota Y, Suzuki Y, Yumori A, Narimatsu H, Koizume S, Sato S, Nakamura Y, Myoba S, Ohtake N, Saji H, Miyagi E, Miyagi Y. Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study. BMC Cancer. 2024;24(1):1058. https:\/\/doi.org\/10.1186\/s12885-024-12827-0.","journal-title":"BMC Cancer"},{"issue":"5","key":"4108_CR14","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s12094-024-03713-z","volume":"27","author":"L Wang","year":"2025","unstructured":"Wang L, Wang M, Wang Z, Wang K, Zhao B, Wang Y, Zheng J, Zhang S. UBE2T is a diagnostic and prognostic biomarker for endometrial cancer. Clin Transl Oncol. 2025;27(5):2067\u201383. https:\/\/doi.org\/10.1007\/s12094-024-03713-z.","journal-title":"Clin Transl Oncol"},{"key":"4108_CR15","doi-asserted-by":"publisher","first-page":"216761","DOI":"10.1016\/j.canlet.2024.216761","volume":"592","author":"R Li","year":"2024","unstructured":"Li R, Yan X, Zhong W, Zheng J, Li X, Liang J, Hu Z, Liu H, Chen G, Yang Y, Zhang J, Qu E, Liu W. Stratifin promotes the malignant progression of HCC via binding and hyperactivating AKT signaling. Cancer Lett. 2024;592:216761. https:\/\/doi.org\/10.1016\/j.canlet.2024.216761.","journal-title":"Cancer Lett"},{"issue":"6","key":"4108_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/cyt.12220","volume":"26","author":"N Itoguchi","year":"2015","unstructured":"Itoguchi N, Nakagawa T, Murata Y, Li D, Shiba-Ishii A, Minami Y, Noguchi M. Immunocytochemical staining for stratifin and OCIAD2 in bronchial washing specimens increases sensitivity for diagnosis of lung cancer. Cytopathology. 2015;26(6):354\u201361. https:\/\/doi.org\/10.1111\/cyt.12220.","journal-title":"Cytopathology"},{"issue":"1","key":"4108_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1186\/s12885-021-08647-1","volume":"21","author":"MX Li","year":"2021","unstructured":"Li MX, Sun XM, Cheng WG, Ruan HJ, Liu K, Chen P, Xu HJ, Gao SG, Feng XS, Qi YJ. Using a machine learning approach to identify key prognostic molecules for esophageal squamous cell carcinoma. BMC Cancer. 2021;21(1):906. https:\/\/doi.org\/10.1186\/s12885-021-08647-1.","journal-title":"BMC Cancer"},{"issue":"4","key":"4108_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","volume":"168","author":"N McGranahan","year":"2017","unstructured":"McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future. Cell. 2017;168(4):613\u201328. https:\/\/doi.org\/10.1016\/j.cell.2017.01.018.","journal-title":"Cell"},{"issue":"11","key":"4108_CR19","doi-asserted-by":"publisher","first-page":"9727","DOI":"10.18632\/aging.205896","volume":"16","author":"D Wang","year":"2024","unstructured":"Wang D, Luo H, Chen Y, Ou Y, Dong M, Chen J, Liu R, Wang X, Zhang Q. 14-3-3\u03c3 downregulation sensitizes pancreatic cancer to carbon ions by suppressing the homologous recombination repair pathway. Aging. 2024;16(11):9727\u201352. https:\/\/doi.org\/10.18632\/aging.205896.","journal-title":"Aging"},{"issue":"10","key":"4108_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/pin.13147","volume":"71","author":"A Shiba-Ishii","year":"2021","unstructured":"Shiba-Ishii A. Significance of stratifin in early progression of lung adenocarcinoma and its potential therapeutic relevance. Pathol Int. 2021;71(10):655\u201365. https:\/\/doi.org\/10.1111\/pin.13147.","journal-title":"Pathol Int"},{"issue":"8","key":"4108_CR21","doi-asserted-by":"publisher","first-page":"e1483","DOI":"10.1111\/aos.14844","volume":"99","author":"S Chauhan","year":"2021","unstructured":"Chauhan S, Sen S, Chauhan SS, Pushker N, Tandon R, Kashyap S, Vanathi M, Bajaj MS. Stratifin in ocular surface squamous neoplasia and its association with p53. Acta Ophthalmol. 2021;99(8):e1483\u201391. https:\/\/doi.org\/10.1111\/aos.14844.","journal-title":"Acta Ophthalmol"},{"issue":"1","key":"4108_CR22","doi-asserted-by":"publisher","first-page":"e2143","DOI":"10.1002\/biof.2143","volume":"51","author":"X Feng","year":"2025","unstructured":"Feng X, Wang Z, Cen M, Zheng Z, Wang B, Zhao Z, Zhong Z, Zou Y, Lv Q, Li S, Huang L, Huang H, Qiu X. Deciphering potential molecular mechanisms in clear cell renal cell carcinoma based on the ubiquitin-conjugating enzyme E2 related genes: identifying UBE2C correlates to infiltration of regulatory T cells. BioFactors. 2025;51(1):e2143. https:\/\/doi.org\/10.1002\/biof.2143.","journal-title":"BioFactors"},{"issue":"2","key":"4108_CR23","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.3892\/mmr.2019.10322","volume":"20","author":"P Hao","year":"2019","unstructured":"Hao P, Kang B, Li Y, Hao W, Ma F. UBE2T promotes proliferation and regulates PI3K\/Akt signaling in renal cell carcinoma. Mol Med Rep. 2019;20(2):1212\u201320. https:\/\/doi.org\/10.3892\/mmr.2019.10322.","journal-title":"Mol Med Rep"},{"issue":"762","key":"4108_CR24","doi-asserted-by":"publisher","first-page":"eadk7399","DOI":"10.1126\/scitranslmed.adk7399","volume":"16","author":"Y Liu","year":"2024","unstructured":"Liu Y, Wang F, Peng D, Zhang D, Liu L, Wei J, Yuan J, Zhao L, Jiang H, Zhang T, Li Y, Zhao C, He S, Wu J, Yan Y, Zhang P, Guo C, Zhang J, Li X, Gao H, Li K. Activation and antitumor immunity of CD8\u2009+\u2009T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid. Sci Transl Med. 2024;16(762):eadk7399. https:\/\/doi.org\/10.1126\/scitranslmed.adk7399.","journal-title":"Sci Transl Med"},{"issue":"1","key":"4108_CR25","doi-asserted-by":"publisher","first-page":"52","DOI":"10.2174\/1389201020666190918104105","volume":"21","author":"M Oplawski","year":"2020","unstructured":"Oplawski M, Dziobek K, Zmarz\u0142y N, Grabarek BO, Kie\u0142basi\u0144ski R, Kieszkowski P, Januszyk P, Talkowski K, Schweizer M, Kras P, Plewka A, Boro\u0144 D. Variances in the level of COX-2 and iNOS in different grades of endometrial cancer. Curr Pharm Biotechnol. 2020;21(1):52\u20139. https:\/\/doi.org\/10.2174\/1389201020666190918104105.","journal-title":"Curr Pharm Biotechnol"},{"key":"4108_CR26","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.3389\/fonc.2020.01202","volume":"10","author":"M Li","year":"2020","unstructured":"Li M, Li M, Wei Y, Xu H. Prognostic and clinical significance of Cyclooxygenase-2 overexpression in endometrial cancer: A Meta-Analysis. Front Oncol. 2020;10:1202. https:\/\/doi.org\/10.3389\/fonc.2020.01202.","journal-title":"Front Oncol"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04108-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04108-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04108-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:05:39Z","timestamp":1790816739000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04108-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4108"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04108-4","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"23 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This retrospective study was approved by the Ethics Committee of zhejiang provincial people's hospital and conducted in accordance with the Declaration of Helsinki and the ethical guidelines of the hospital\u2019s institutional review board. The protocol was reviewed and approved by the Ethics Committee of zhejiang provincial people'sHospital in accordance with the national ethical guidelines for biomedical research involving human subjects. All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments. As this was a retrospective analysis of archival tissue samples and clinical data collected between January 2021 and January 2024, the requirement for individual informed consent was waived by the Ethics Committee of zhejiang provincial people's Hospital due to the retrospective nature of the study and the use of anonymized data. All patient identifiers were removed, and data were analyzed anonymously. The waiver of consent for the retrospective data analysis was granted in accordance with national regulations for retrospective studies using de-identified patient data.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1396"}}